Biological E. Limited

Last updated

Biological E Limited
Company type Private
Industry Biotechnology, Biopharmaceuticals
Founded1953;71 years ago (1953)
FounderDatla Venkata Krishnam Raju
Headquarters Jubilee Hills, Hyderabad, Telangana, India
Key people
Mahima Datla (CEO and Managing Director) [1]
RevenueIncrease2.svg₹3,820 crore (US$460 million) (FY23) [2]
Increase2.svg₹953 crore (US$110 million) (FY23) [2]
Number of employees
2,500
Website www.biologicale.com

Biological E Limited (also known as BioE) is an Indian biotechnology and biopharmaceutical company based in Hyderabad, Telangana. It specialises in the areas of low-cost vaccine production. [3]

Contents

History

The company was founded by Dr. D.V.K. Raju and Mr. G.A.N. Raju in 1953 as Biological Products Private Limited. It was among the first private sector companies in India to manufacture biological products. [4] It pioneered Heparin production in India. [5]

In 1964, Evans Medicals, a U.K. based Pharma Company, which later got merged with Glaxo SmithKline acquired 40% stake in the company, which was subsequently bought back by the promoters in 1995.[ citation needed ]

During the 1960s and 70s, Biological E developed formulations in cough and digestive enzymes, started manufacturing anti-tetanus serum, and launched anti-TB drugs, TT and DTP vaccines. [5]

Biological E embarked specialise in low-cost vaccines manufacturing. The company started manufacturing its flagship vaccine product, Pentavalent (DTP Hib HepB) in 2008. [5] Biological E is a major supplier of vaccines to international development and aid organisations such as WHO, UNICEF, BMGF. [5]

COVID-19 vaccine development

During the COVID-19 pandemic, the company signed a pact with Baylor College of Medicine, Texas Children's Hospital and Dynavax Technologies to develop a COVID-19 vaccine. [6] [7] The vaccine Corbevax [8] /Bio E COVID-19 was expected to roll out in 2021 with 75 to 80 million doses manufactured per month; the production was expected to reach 1 billion doses by the end of 2022 under the Quad initiative. [9] [10]

In August 2020, the company signed a deal with Johnson & Johnson to manufacture the latter's vaccine candidate at its Hyderabad facility. [11] In February 2021, it announced that it would produce over 600 million doses of the single-dose Janssen vaccine annually. [12] [13]

Related Research Articles

The pharmaceutical industry in India was valued at an estimated US$42 billion in 2021 and is estimated to reach $130 billion by 2030. India is the world's largest provider of generic medicines by volume, with a 20% share of total global pharmaceutical exports. It is also the largest vaccine supplier in the world by volume, accounting for more than 60% of all vaccines manufactured in the world. Indian pharmaceutical products are exported to various regulated markets including the US, UK, European Union and Canada.

Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. It develops vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and it provides medical devices for biodefense purposes.

Serum Institute of India (SII) is an Indian multinational biotechnology and biopharmaceuticals company, based in Pune. It is the world's largest manufacturer of vaccines by volume. It was founded by Cyrus Poonawalla in 1966 and is a part of Cyrus Poonawalla Group.

<span class="mw-page-title-main">Indian Immunologicals Limited</span> Subsidiary of National Dairy Development Board

Indian Immunologicals Limited (IIL) is a subsidiary of the National Dairy Development Board. It is based in Hyderabad, Telangana, India. IIL is registered in India as a Public Limited Company under the Companies Act, 1956, It was established in 1982 by the National Dairy Development Board.

<span class="mw-page-title-main">Novavax</span> American biotechnology company

Novavax, Inc. is an American biotechnology company based in Gaithersburg, Maryland, that develops vaccines to counter serious infectious diseases. Prior to 2020, company scientists developed experimental vaccines for influenza and respiratory syncytial virus (RSV), as well as Ebola and other emerging infectious diseases. During 2020, the company redirected its efforts to focus on development and approval of its NVX-CoV2373 vaccine for COVID-19.

<span class="mw-page-title-main">Maria Elena Bottazzi</span> Hondurean microbiologist

Maria Elena Bottazzi is an American microbiologist. As of 2024 she is associate dean of the National School of Tropical Medicine at Baylor College of Medicine, as well as Distinguished Professor of Biology at Baylor University, Waco, Texas. She is editor-in-chief of Springer's Current Tropical Medicine Reports. She and Peter Hotez led the team that designed COVID-19 vaccine Corbevax.

<span class="mw-page-title-main">Convidecia</span> Vaccine against COVID-19

AD5-nCOV, trade-named Convidecia, is a single-dose viral vector vaccine for COVID-19 that is also used as an inhaled booster. It was developed by CanSino Biologics, with Phase III trials conducted in Argentina, Chile, Mexico, Pakistan, Russia, and Saudi Arabia with 40,000 participants.

<span class="mw-page-title-main">CanSino Biologics</span> Chinese vaccine company

CanSino Biologics, often abbreviated as CanSinoBIO, is a Chinese vaccine company.

The first case of the COVID-19 pandemic in India was reported on 30 January 2020, originating from China. Slowly, the pandemic spread to various states and union territories including the state of Telangana. The first case was recorded in this region on 2 March from a man who had travel history with the UAE.

<span class="mw-page-title-main">Bharat Biotech</span> Indian multinational biotechnology company and vaccine manufacturer

Bharat Biotech International Limited (BBIL) is an Indian multinational biotechnology company based in Hyderabad, which is engaged in drug discovery, drug development, and the manufacture of vaccines, biotherapeutics, pharmaceuticals and healthcare products.

<span class="mw-page-title-main">Covaxin</span> Vaccine against COVID-19

Covaxin is a whole inactivated virus-based COVID-19 vaccine developed by Bharat Biotech in collaboration with the Indian Council of Medical Research - National Institute of Virology.

<span class="mw-page-title-main">Janssen COVID-19 vaccine</span> Vaccine against COVID-19

The Janssen COVID‑19 vaccine, (Ad26.COV2.S) sold under the brand name Jcovden, is a COVID‑19 vaccine that was developed by Janssen Vaccines in Leiden, Netherlands, and its Belgian parent company Janssen Pharmaceuticals, a subsidiary of American company Johnson & Johnson.

<span class="mw-page-title-main">COVID-19 vaccination in India</span> Immunisation programme against COVID-19 in India

India began administration of COVID-19 vaccines on 16 January 2021. As of 4 March 2023, India has administered over 2.2 billion doses overall, including first, second and precautionary (booster) doses of the currently approved vaccines. In India, 95% of the eligible population (12+) has received at least one shot, and 88% of the eligible population (12+) is fully vaccinated.

<span class="mw-page-title-main">History of COVID-19 vaccine development</span> Scientific work to develop a vaccine for COVID-19

SARS-CoV-2, the virus that causes COVID-19, was isolated in late 2019. Its genetic sequence was published on 11 January 2020, triggering an urgent international response to prepare for an outbreak and hasten the development of a preventive COVID-19 vaccine. Since 2020, vaccine development has been expedited via unprecedented collaboration in the multinational pharmaceutical industry and between governments. By June 2020, tens of billions of dollars were invested by corporations, governments, international health organizations, and university research groups to develop dozens of vaccine candidates and prepare for global vaccination programs to immunize against COVID‑19 infection. According to the Coalition for Epidemic Preparedness Innovations (CEPI), the geographic distribution of COVID‑19 vaccine development shows North American entities to have about 40% of the activity, compared to 30% in Asia and Australia, 26% in Europe, and a few projects in South America and Africa.

<span class="mw-page-title-main">COVID-19 vaccination in South Africa</span> Plan to immunize against COVID-19 in South Africa

COVID-19 vaccination in South Africa is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.

<span class="mw-page-title-main">COVID-19 vaccination in Africa</span> Immunisation programme against COVID-19 in Africa

COVID-19 vaccination programs are ongoing in the majority countries and territories in Africa, with 51 of 54 African countries having launched vaccination programs by July 2021. As of October 2023, 51.8% of the continent's population is fully vaccinated with over 1084.5 million doses administered.

<span class="mw-page-title-main">Corbevax</span> Protein subunit vaccine against COVID-19

Corbevax is a protein subunit COVID-19 vaccine developed by Texas Children's Hospital Center for Vaccine Development and Baylor College of Medicine in Houston, Texas and Dynavax technologies based in Emeryville, California. It is licensed to Indian biopharmaceutical firm Biological E. Limited (BioE) for development and production.

<span class="mw-page-title-main">COVID-19 vaccination in South Korea</span> Plan to immunize against COVID-19

COVID-19 vaccination in South Korea is an ongoing immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.

<span class="mw-page-title-main">COVID-19 vaccination in Bangladesh</span> Immunisation programme against COVID-19 in Bangladesh

Bangladesh began the administration of COVID-19 vaccines on 27 January 2021 while mass vaccination started on 7 February 2021.

References

  1. ↑ "Hyderabad's Biological E: The Dark Horse In India's Vaccine Race". Forbes India. Retrieved 24 May 2021.
  2. 1 2 "Biological E. Limited: Ratings reaffirmed". ICRA. Retrieved 25 February 2024.
  3. ↑ "Biological E cuts children's vaccine price by 30%". thehindubusinessline.com/. 19 April 2013. Retrieved 19 April 2013.
  4. ↑ "Biological E Limited" (PDF). icra.in. Retrieved 13 March 2012.
  5. 1 2 3 4 "Setting up manufacturing facilities for Pneumococcal Conjugate Vaccine" (PDF). www.tdb.gov.in. Technology Development Board . Retrieved 25 April 2021.PD-icon.svg This article incorporates text from this source, which is in the public domain .
  6. ↑ Leo, Leroy (16 November 2020). "Biological E initiates human trials of vaccine". mint.
  7. ↑ "Coronavirus | Biological E. inks pacts with Johnson & Johnson, Baylor College of Medicine on vaccine". The Hindu. 13 August 2020. Retrieved 21 March 2021.
  8. ↑ Bharadwaj, Swati (3 June 2021). "Bio E to get Rs 1,500 crore advance from government to reserve 30 crore doses of Corbevax". The Times of India. Archived from the original on 3 June 2021. Retrieved 3 June 2021.
  9. ↑ "Meet Bio E: India's Oldest Private Vaccine Maker Making 1 Billion Covid Doses". IndiaTimes. 2 May 2021. Retrieved 24 May 2021.
  10. ↑ "Biological E covid vaccine: Biological E set for Covid vaccine rollout by August". The Times of India. Retrieved 24 May 2021.
  11. ↑ "Biological E to manufacture Janssen's Covid-19 vaccine". www.pharmaceutical-technology.com. Retrieved 24 May 2021.
  12. ↑ "Biological E looking to make 600 million Johnson and Johnson vaccine shots a year". The Times of India. Retrieved 21 March 2021.
  13. ↑ Leo, Leroy (20 March 2021). "Biological E: The mass producer of Johnson & Johnson vaccine". mint. Retrieved 21 March 2021.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.